Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Significance of MiR-146a quantification in human blood plasma for the diagnosis of colorectal cancer. / Shirshova, A. N.; Shamovskaya, D. A.; Boyarskikh, U. A. и др.
в: Bulletin of Russian State Medical University, Том 6, № 4, 01.07.2017, стр. 28-33.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Significance of MiR-146a quantification in human blood plasma for the diagnosis of colorectal cancer
AU - Shirshova, A. N.
AU - Shamovskaya, D. A.
AU - Boyarskikh, U. A.
AU - Apalko, S. V.
AU - Leskov, L. S.
AU - Sokolov, A. V.
AU - Kovalenko, S. A.
AU - Scherbak, S. G.
AU - Pikalov, I. V.
AU - Kel, A. E.
AU - Filipenko, M. L.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Colorectal cancer (CRC) is one of the most common cancer types in the world. Timely diagnosis of CRC and adenomatous polyps aided by effective screening techniques can considerably reduce mortality from this disease. MicroRNAs constitute a new class of promising biomarkers for a range of human diseases including cancer. The following article assesses the diagnostic significance of miR-146a concentrations in the blood plasma of patients with colorectal cancer. The main group included patients with stages I to III colorectal cancer (n = 102); the control group comprised patients with chronic colitis, nonspecific ulcerative colitis and Crohn’s disease (n = 58) and healthy individuals (n = 42). MicroRNA levels were quantified by reverse-transcription real-time PCR, revealing significantly higher miR-146a concentrations in the samples of patients with CRC than in the controls (p < 0.0001). The optimal diagnostic sensitivity determined by ROC analysis was 47.3 %, specificity was 91.5 %, with AUC = 0.79 ± 0.018. Our findings demonstrate that the studied approach does not have sufficient specificity, but still suggest that miR-146a can be included into screening tests based on quantification of other microRNAs with improved specificity.
AB - Colorectal cancer (CRC) is one of the most common cancer types in the world. Timely diagnosis of CRC and adenomatous polyps aided by effective screening techniques can considerably reduce mortality from this disease. MicroRNAs constitute a new class of promising biomarkers for a range of human diseases including cancer. The following article assesses the diagnostic significance of miR-146a concentrations in the blood plasma of patients with colorectal cancer. The main group included patients with stages I to III colorectal cancer (n = 102); the control group comprised patients with chronic colitis, nonspecific ulcerative colitis and Crohn’s disease (n = 58) and healthy individuals (n = 42). MicroRNA levels were quantified by reverse-transcription real-time PCR, revealing significantly higher miR-146a concentrations in the samples of patients with CRC than in the controls (p < 0.0001). The optimal diagnostic sensitivity determined by ROC analysis was 47.3 %, specificity was 91.5 %, with AUC = 0.79 ± 0.018. Our findings demonstrate that the studied approach does not have sufficient specificity, but still suggest that miR-146a can be included into screening tests based on quantification of other microRNAs with improved specificity.
KW - Biomarker
KW - Cancer research
KW - Cel-238
KW - Colorectal cancer
KW - MicroRNA
KW - MiR-146a
KW - Polymerase chain reaction
KW - Reverse transcription
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=85032825105&partnerID=8YFLogxK
U2 - 10.24075/brsmu.2017-04-05
DO - 10.24075/brsmu.2017-04-05
M3 - Article
AN - SCOPUS:85032825105
VL - 6
SP - 28
EP - 33
JO - Bulletin of Russian State Medical University
JF - Bulletin of Russian State Medical University
SN - 2500-1094
IS - 4
ER -
ID: 9753888